Beth E. Meyerson

Beth E. Meyerson

Auto-generated profile, based on publicly available information

Beth E. Meyerson

Comprehensive Center for Pain and Addiction at the University of Arizona Health Sciences. Tucson, AZ, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in International Journal of Drug Policy
Verified
Journal Article
Closed access
BMBeth E. Meyerson
Beth E. Meyerson
DRDanielle M. Russell
Danielle M. Russell
MKMichaela Kichler
Michaela Kichler
TATyson Atkin
Tyson Atkin
GFGraeme Fox
Graeme Fox
HCHaley B. Coles
Haley B. Coles

1 July 2018 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
BMB.E. Meyerson
B.E. Meyerson
JAJ.D. Agley
J.D. Agley
ADA. Davis
A. Davis
WJW. Jayawardene
W. Jayawardene
AHA. Hoss
A. Hoss
RGR. Gassman
R. Gassman
While naloxone, the overdose reversal medication, has been available for decades, factors associated with its availability through pharmacies remain unclear. Studies suggest that policy and pharmacist beliefs may impact availability. Indiana passed a standing order law for naloxone in 2015 to increase access to naloxone. To identify factors associated with community pharmacy naloxone stocking and dispensing following the enactment of a statewide naloxone standing order. A 2016 cross-sectional census of Indiana community pharmacists was conducted following a naloxone standing order. Community, pharmacy, and pharmacist characteristics, and pharmacist attitudes about naloxone dispensing, access, and perceptions of the standing order were measured. Modified Poisson and binary logistic regression models attempted to predict naloxone stocking and dispensing, respectively. Over half (58.1%) of pharmacies stocked naloxone, yet 23.6% of pharmacists dispensed it. Most (72.5%) pharmacists believed the standing order would increase naloxone stocking, and 66.5% believed it would increase dispensing. Chain pharmacies were 3.2 times as likely to stock naloxone. Naloxone stocking was 1.6 times as likely in pharmacies with more than one full-time pharmacist. Pharmacies where pharmacists received naloxone continuing education in the past two years were 1.3 times as likely to stock naloxone. The attempted dispensing model yielded no improvement over the constant-only model. Pharmacies with larger capacity took advantage of the naloxone standing order. Predictors of pharmacist naloxone dispensing should continue to be explored to maximize naloxone access.

1 June 2018 in International Journal of Drug Policy
Verified
Journal Article
Open access
BMBeth E. Meyerson
Beth E. Meyerson
ADAlissa Davis
Alissa Davis
JAJon Agley
Jon Agley
DSDavid J. Shannon
David J. Shannon
CLCarrie A. Lawrence
Carrie A. Lawrence
RGRuth Gassman
Ruth Gassman
Pharmacies have much to contribute to the health of people who inject drugs (PWID) and to community efforts in HIV and hepatitis C (HCV) prevention through syringe access. However, little is known about what predicts pharmacy syringe sales without a prescription. To identify factors predicting pharmacy syringes sales to PWID. A hybrid staggered online survey of 298 Indiana community pharmacists occurred from July-September 2016 measuring pharmacy policy, practice, and pharmacist perceptions about syringe sales to PWID. Separate bivariate logistical regressions were followed by multivariable logistic regression to predict pharmacy syringe sales and pharmacist comfort dispensing syringes to PWID. Half (50.5%) of Indiana pharmacies sold syringes without a prescription to PWID. Pharmacy syringe sales was strongly associated with pharmacist supportive beliefs about syringe access by PWID and their comfort level selling syringes to PWID. Notably, pharmacies located in communities with high rates of opioid overdose mortality were 56% less likely to sell syringes without a prescription than those in communities with lower rates. Pharmacist comfort dispensing syringes was associated with being male, working at a pharmacy that sold syringes to PWID and one that stocked naloxone, having been asked about syringe access by medical providers, and agreement that PWID should be able to buy syringes without a prescription. As communities with high rates of opioid overdose mortality were less likely to have pharmacies that dispensed syringes to PWID, a concerted effort with these communities and their pharmacies should be made to understand opportunities to increase syringe access. Future studies should explore nuances between theoretical support for syringe access by PWID without a prescription and actual dispensing behaviors. Addressing potential policy conflicts and offering continuing education on non-prescription syringe distribution for pharmacists may improve comfort distributing syringes to PWID, and therefore increase pharmacy syringe sales.

21 June 2016 in Health Communication
Verified
Journal Article
Closed access
MVMaria K. Venetis
Maria K. Venetis
BMBeth E. Meyerson
Beth E. Meyerson
LFL. Brooke Friley
L. Brooke Friley
AGAnthony Gillespie
Anthony Gillespie
AOAnita Ohmit
Anita Ohmit
CSCleveland G. Shields
Cleveland G. Shields
This study examines lesbian, gay, and bisexual patients’ disclosure patterns of sexual orientation to health care providers. Using a semistructured interview format, researchers conducted interviews with 24 lesbian, gay, bisexual, and queer (LGBQ) adults about sexual orientation disclosure strategies. All interviews were transcribed and independently coded using thematic analysis. Results suggest that patient sexual orientation disclosure may be patient initiated and may occur to clarify or correct provider misinformation. Participants disclosed their orientation early in the medical visit during introductions, during small talk with the provider, and during the history-taking phase of the visit. Participants characterized sexual orientation disclosures as presented with minimal information, casually, and often indirectly. Practical and theoretical implications are discussed.

1 May 2013 in Public Health Reports®
Verified
Journal Article
Closed access
BMBeth E. Meyerson
Beth E. Meyerson
PRPriscilla T. Ryder
Priscilla T. Ryder
CRCarriann Richey-Smith
Carriann Richey-Smith

1 May 2020 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Open access
BMB.E. Meyerson
B.E. Meyerson
JAJ.D. Agley
J.D. Agley
WJW. Jayawardene
W. Jayawardene
LEL.A. Eldridge
L.A. Eldridge
PAP. Arora
P. Arora
TMT. Moehling
T. Moehling
Evidence-based harm reduction intervention components which might benefit pharmacy patients have not been integrated and studied. To investigate the feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C called PharmNet. Indiana managing pharmacists were surveyed in 2018 to assess the feasibility and acceptability of an intervention for opioid misuse screening, brief intervention, syringe and naloxone dispensing, and referrals provision. The Consolidated Framework for Implementation Research informed the survey development and analysis. The sample included 303 (30.8%) pharmacists; 215 (70.9%) provided detailed written comments. Intervention Characteristics: 83.3% believed PharmNet would benefit patients, and that staff could deliver the intervention with adequate training (70.0%). Inner Setting: While 77.2% believed their pharmacy culture supported practice change, 57.5% of chain pharmacists believed their pharmacies would not have time for PharmNet. Outer Setting: 73.3% believed additional addiction and overdose screening is needed in their community, and pharmacies should offer new services to help reduce opioid overdose and addiction among their patients (79.5%). A vast majority (97.7%) were asked by patients in the past 2 years about syringe related issues; 67.7% were asked about syringes for non-prescription injection drug use. Individuals Involved: While 62.4% believed PharmNet was within pharmacy scope of practice and 90.1% were comfortable consulting about syringe use, pharmacists reported that they had limited control over the implementation environment. 38.0% of pharmacists indicated interest in advising the development of PharmNet. An implementation trial of a modified version of PharmNet is likely feasible; yet will be challenged by structural pressures particularly in chain pharmacies. Successful implementation will involve the development of resources and policy components to manage outer and inner setting characteristics and align the intervention to the implementation environment.